跳至主要内容
临床试验/NCT04815291
NCT04815291终止不适用

STREAMLoc- Streamlined Localization Using SCOUT® at Biopsy: An Analysis of Process Improvement, Cost Savings and Enhanced Patient Experience.

Merit Medical Systems, Inc.4 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2022年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
93
试验地点
4
主要终点
Number of Participants Invasive Visits

研究概览

简要总结

This registry is intended to demonstrate the utility of SCOUT® in the Canadian public and US healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to harm. The efficacy and safety of this system will be further assessed, as well as the acceptance of clinicians and patients.

详细描述

This registry is intended to demonstrate the utility of SCOUT® in the Canadian public and US healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to harm (i.e., radiation, COVID-19 exposure, patient emotional trauma). By assessing the utility of reflector insertion at the time of biopsy, this study will be able to measure the impact on patient visits to the breast center for invasive procedures between biopsy and surgery, and quantify this value to the public healthcare system. The efficacy and safety of this system will be further assessed, as well as the acceptance of clinicians and patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Woman >18 years and < 80 years of age;
  • Classified as Breast Imaging Reporting and Data System (BI-RADS) 4C or 5;
  • Lesion depth is < 6 cm from skin surface;
  • Non-palpable lesions;
  • Informed consent obtained.

排除标准

  • Multicentric breast cancer;
  • Pregnant or lactating;
  • Known or suspected nickel-titanium allergy.

结局指标

主要结局

Number of Participants Invasive Visits

时间窗: through study completion, an average of 6 months

Number of visits to the breast centre for an invasive procedure between biopsy and surgery

次要结局

  • Performance(through study completion; an average of 6 months)
  • Number of Participants With Adverse Events(through study completion; an average of 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验